Company / Cost of Revenue
BIOCRYST PHARMACEUTICALS INC Cost of Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$19.1M
FY2025
5-year range
$4.5M / $19.1M
FY2021-FY2025
Trend
+55.5%
vs FY2024
Sector context
#66 of 85
Health Care
What the data says
BIOCRYST PHARMACEUTICALS INC's cost of revenue of $19M is lower than 78% of companies in the Health Care sector (FY2025). Cost of Revenue has fluctuated over the past 9 years, ranging from $1M in FY2017 to $19M in FY2025.
Based on SEC 10-K filings.
$19M in FY2025 with a 5-year CAGR of +65.2%.
Increased from $4M to $19M over the past 2 years.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- +43.9%
- 5-Year CAGR
- +65.2%
- 10-Year CAGR
- -
Sector benchmark
Top 22% in Health CareTop 22% of 85This company $19.1M Sector average $2.0B
▼
-99.0% below sector average
Key checks
Key Insights
- 5-year CAGR of +65.2%, indicating consistent growth.
- In FY2025, cost of revenue increased 55.5% year-over-year.
- Ranks #66 out of 85 companies in the Health Care sector.
- Lowest cost of revenue in the period was in FY2017.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $19.1M | +55.5% |
| FY2024 | $12.3M | +173.8% |
| FY2023 | $4.5M | -30.1% |
| FY2022 | $6.4M | -11.4% |
| FY2021 | $7.2M | +366.4% |
| FY2020 | $1.6M | -58.4% |
| FY2019 | $3.7M | - |
| FY2018 | - | - |
| FY2017 | $1.1M | -50.3% |
| FY2016 | $2.3M | +67.9% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026